title: Perioperative management of trauma patients admitted on clopidogrel (Plavix). A survey of orthopaedic departments across the United Kingdom.
abstract: BACKGROUND
  Clopidogrel (Plavix) is an anti-platelet drug recommended as lifelong treatment by NICE for all patients following stroke, MI, and peripheral vascular disease. It is also indicated for short-term use following cardiac stent insertion. It irreversibly inhibits platelets for up to 7 days. Current recommendations are to stop treatment 7 days before elective surgery. Current evidence shows that delay to surgery more than 4 days in patients with hip fractures increases postoperative mortality.
  
  
  OBJECTIVE
  To determine current practice of orthopaedic surgeons in their management of patients taking clopidogrel admitted following a hip fracture to trauma units in the UK with respect to its peri-operative withdrawal and subsequent timing of surgery. To perform a review of the available literature and produce a suggested protocol for the peri-operative management of this rapidly increasing cohort of patients.
  
  
  METHODS
  National postal survey.
  
  
  METHODS
  Orthopaedic consultants representing each unit receiving trauma patients in the United Kingdom.
  
  
  RESULTS
  There was a 57% response rate (139/244 UK trauma units). 41% (56) stop clopidogrel and operate immediately, 11% (15) stop clopidogrel for between 5 and 10 days pre-operatively, 10% (14) stop clopidogrel for 10 days preoperatively, 19% (26) continue clopidogrel and operate immediately, 19% (26) have another protocol. 15% (20) have written departmental guidelines. 2%(3) quoted published evidence for their practice.
  
  
  CONCLUSIONS
  This study demonstrates that there are a wide variety of practices, largely based on anecdotal evidence. Most units (85%) have no formal guidelines. There is evidence in the cardiac literature of increased intra-operative bleeding in patients operated on while taking clopidogrel. There is likely to be an exponential rise in such patients presenting to trauma units and further research is required to guide best practice. Following review of the literature we propose an interim protocol for the withdrawal and resumption of clopidogrel peri-operatively in patients with hip fractures.
authors.affiliation: Wansbeck Hospital, Woodhorn Lane, Ashington, Northumberland, UK. dominic@scottinman.freeserve.co.uk
authors.forename: Dominic S
authors.initials: DS
authors.lastname: Inman
authors.forename: Yusuf
authors.initials: Y
authors.lastname: Michla
authors.forename: Paul F
authors.initials: PF
authors.lastname: Partington
mesh_terms: D002985:Clinical Protocols; D000077144:Clopidogrel; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine; D019538:Health Care Surveys; D006620:Hip Fractures / Q000601:surgery*; D006801:Humans; D019990:Perioperative Care / Q000379:methods*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D011364:Professional Practice / Q000706:statistics & numerical data; D013988:Ticlopidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D013997:Time Factors
chemical_list: D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine